Related Experiment Video

Updated: Jun 5, 2026

Shock Wave Application to Cell Cultures
05:39

Shock Wave Application to Cell Cultures

Published on: April 8, 2014

[Cardiac shock wave therapy--a new method for treatment of advanced coronary disease and refractory angina]

Maria Sobczak1, Jarosław D Kasprzak

  • 1II Katedra i Klinika Kardiologii, Uniwersytet Medyczny w Łodzi, Łódź. maria.sobczak@wp.pl

Kardiologia Polska
|December 22, 2010
PubMed

Insights

New non-invasive cardiac shock wave therapy shows promise for treating advanced ischemic heart disease and refractory angina. This mechanical shock wave method offers a potential new option for patients with limited therapeutic choices.

Area of Science:

  • Cardiology
  • Biomedical Engineering

Context:

  • Advanced ischemic heart disease and refractory angina remain challenging clinical problems with limited treatment options.
  • Current pharmacological and revascularization techniques are insufficient for a significant patient subset.
  • Alternative therapies like laser revascularization and cell therapy have been explored.

Purpose:

  • To present non-invasive cardiac shock wave therapy (SWT) as a novel treatment modality.
  • To review the available clinical information on the therapeutic potential of SWT in refractory angina.
  • To highlight the mechanism of action involving low-frequency ultrasound with ECG gating.

Summary:

  • Non-invasive cardiac SWT utilizes percutaneous application of low-frequency mechanical shock waves, guided by ECG gating and echocardiographic monitoring.
  • This therapy has a history of successful application in various medical fields including nephrology, orthopedics, and dermatology.
  • The paper reviews its potential for treating advanced ischemic heart disease and refractory angina pectoris.

Impact:

  • Cardiac SWT offers a promising, non-invasive therapeutic avenue for patients with chronic refractory angina.
  • Successful application in other fields suggests potential efficacy and safety in cardiology.
  • Further research is needed to confirm its role in cardiovascular medicine.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...